$2.36
$0.00 (0.00%)
End-of-day quote: 05/18/2024
NasdaqGM:ESPR
Esperion Therapeutics Annual Report
| Year | Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$116.33M | $75.48M | $78.45M | $227.55M | $148.36M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | |
| GM % | Gross Margin % |
|
-11.21% | -93.30% | -53.21% | 34.37% | -18.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| OM | Operating Margin |
|
-133.72% | -237.83% | -272.13% | -53.35% | -62.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| EPS | Earnings Per Share |
|
$0.00 | $-2.03 | $-3.52 | $-9.31 | $-5.23 | $-3.59 | $-7.54 | $-6.98 | $-3.33 | $-2.26 | $-2.22 | $-2.98 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| PR % | Payout Ratio % |
|
-0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | |
| Sha. | Shares |
|
118.21m | 74.57m | 60.88m | 25.92m | 27.5m | 26.82m | 26.3m | 22.56m | 22.52m | 20.34m | 15.34m | |
| OCF | Operating Cash Flow |
|
$-135.49M | $-174.83M | $-263.81M | $-85.18M | $-70.34M | $-148.64M | $-131.30M | $-47.73M | $-38.16M | $-32.02M | $-18.11M | |
| FCF | Free Cash Flow |
|
$-65.00M | $-174.83M | $-263.81M | $-86.05M | $-71.29M | $-148.79M | $-131.32M | $-47.82M | $-38.48M | $-32.89M | $-18.14M | |
| FCFS | Free Cash Flow Per Share |
|
$-1.31 | $-2.63 | $-9.13 | $-3.59 | $-2.63 | $-5.56 | $-5.49 | $-2.12 | $-1.75 | $-2.01 | $-2.30 |
